Equity Overview
Price & Market Data
Price: $1.31
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $119,009,176
Volume: 0
Performance Metrics
1 Week: 1.55%
1 Month: 6.50%
3 Months: 14.91%
6 Months: 3.97%
1 Year: -14.94%
YTD: 25.96%
Company Details
Employees: 15
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.